Uncategorized

GeneCode has secured a grant of approximately €1.5 million from the Estonian Business and Innovation Agency to advance its Parkinson’s drug development project. The funding, along with GeneCode’s own contribution, will help complete preclinical studies and pave the way for first-in-human study. Read more

Parkinson’s disease is on the rise. According to the World Health Organization, the prevalence of the neurodegenerative disease has doubled worldwide since the turn of the century. Is there anything we can do about it? Read more about prof. Saarma’s research and GeneCode’s mission here: https://www.freethink.com/health/the-exciting-research-that-may-cure-parkinsons

GeneCode selected among the most promising biotech companies in the European Union. Read press release

At GeneCode, we’re thrilled to share a major milestone in our research journey. With the recent €1.6M grant from Enterprise Estonia (EAS), we are set to expand our GDNF Mimetics Platform to address ALS, Retinitis Pigmentosa, and Inflammatory Bowel Disease. Read more

GeneCode has been named one of the TOP 5 best biotech companies to watch in 2024 by The Silicon Review! GeneCode research group led by Prof. Dr. Saarma is investigating the structure, biology, and therapeutic potential of neurotrophic factors. We specifically study the GDNF family neurotrophic factors and their receptors. Prof. Dr. Saarma’s exclusive interview is available…

The Life Sciences Review has nominated GeneCode Ltd. among TOP10 Drug Discovery and Development Solutions Provider in Europe 2023. GeneCode Reprint (PDF) GeneCode Ltd | Top Drug Discovery and Development Solutions Company in Europe-2023 (lifesciencesreview.com)

GeneCode’s R&D project has received tremendous backing from Enterprise Estonia, and we are grateful for their critical support. In collaboration with them, we have taken time to reflect on our journey with them and Argobio and look ahead to the future. https://investinestonia.com/follow-the-science-end-up-in-estonia/

European Innovation Council (EIC) Accelerator is providing € 16 million to support the development of a drug and treatment to slow the progression in Parkinson’s disease. The funding to GeneCode for the Kevad Bio project developed in collaboration with Argobio is split into a € 1.7 million grant and € 14.3 million in equity investments. This…

Launch of WHO’s Parkinson disease technical brief. Globally, the prevalence of Parkinson disease (PD) has doubled in the past 25 years with global estimates in 2019 showing over 8.5 million individuals living with PD. Disability and death due to PD are increasing faster than for any other neurological disorder. Current estimates suggest that, in 2019,…

Excellent start to the year 2022. GeneCode to Accelerate GDNF Mimetics program on Parkinson’s Disease with 2 million euro R&D Grant from Enterprise Estonia: PR_Genecode_EAS_EN_13.01.2022